List view / Grid view
In this exclusive interview, Torsten Madsen, CEO of Hoba Therapeutics, highlights the current clinical development landscape, challenges, and opportunities for pain management medicines.
Dr Mikael Sodergren, Chief Medical Officer at Curaleaf International, discusses the challenges of developing and researching medical cannabis products and how the European medical cannabis ecosystem is well placed to overcome them.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a UK manufacturing facility good manufacturing practice (GMP) registration for its cannabis API.
New data from the UK shows 86 percent of pain patients found medicinal cannabis more effective than any other medication, including opioids.
NICE has said commonly used treatments for chronic primary pain such as paracetamol have little or no evidence that they work and should not be prescribed for the condition.
The toxicity of crotoxin has been significantly reduced by combining it with nanostructured SBA-15 silica, used in vaccine formulations.
The NICE and NHS have announced their draft recommendations for the prescribed use of cannabis-based treatments.
Project TWENTY21, a nationwide study to investigate medicinal cannabis, has launched in the UK in order to collect data on the therapeutics.
Researchers find no evidence of effectiveness in three compounded topical pain creams specially formulated to treat localised chronic pain...
A sugar pill could benefit patients suffering from chronic pain with specific brain anatomy and psychological traits...
The NIH Health Care Systems Research Collaboratory has announced five new awards...
